Saturday, October 08, 2016 3:53:45 PM
Heat Biologics Reports HS-410 Phase 1 Bladder Cancer Trial Results at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
HS-410 had a positive safety profile and was well-tolerated Unprecedented increase in intratumoral CD8+ T cells following vaccination DURHAM, N.C., Nov. 6, 2015 (GLOBE NEWSWIRE)
-- Heat Biologics, Inc. ("Heat") (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient's immune system against cancer, announced results from its Phase 1 trial to evaluate safety and immune response to HS-410 (vesigenurtacel-L), after standard of care Bacillus Calmette-Guérin (BCG), for the treatment of high-risk, non-muscle invasive bladder cancer (NMIBC). HS-410 had a positive safety profile and was well-tolerated with no patients discontinuing the trial due to adverse events. Furthermore, no serious adverse events were reported, and 7 out of 10 patients had no documented recurrence of cancer >1 year after standard of care surgery. Significantly, 3 out of 4 patients with carcinoma in situ (CIS), the patient population least responsive to standard of care, did not recur. HS-410 elicited a broad-based (polyclonal) expansion of patient T cells and a high level of CD8+ tumor-infiltrating lymphocytes (TILs); CD8+ TILs are essential to an effective antitumor response. Additionally, HS-410 shared 15 or more tumor antigens in common with those expressed on the patients' cancer cells, indicating HS-410's ability to target a broad range of tumor antigens for all patients treated to date. These data confirm previous clinical findings regarding the unique mechanism of action for HS-410 and for our ImPACT and ComPACT platform technologies. Moreover, third-party analysis of blinded samples demonstrated a strong correlation between baseline characteristics of TILs by T cell receptor (TCR) sequencing and clinical outcome. Specifically, the 7 patients who remain disease free exhibited the greatest clonal expansion of intratumoral T cells (p-value 0.0126). "We are delighted to see an immune response within tumors that is consistent with the HS-410 mechanism of action and which correlates with clinical outcome. Specifically, we see that HS-410 has a high degree of overlap with patient tumor antigens, stimulates polyclonal T cell proliferation and leads to a distinct immune signature in responding to patient tumors," said Taylor Schreiber, M.D., Ph.D., Heat's Chief Scientific Officer. "Analysis of the pre- and post-treatment biopsies provides clear evidence that the HS410-stimulated immune response reaches the tumor microenvironment and increases CD8+ T cells at levels which have not been published for other vaccines or BCG alone."
"Conversion of tumors from low TIL density to high TIL density following treatment with HS-410 holds great promise for the treatment of the majority of cancer patients who have tumors that are initially TIL negative and have limited response to cancer immunotherapy," added Llew Keltner, M.D., Ph.D., Associate Professor, Case Western Reserve University School of Medicine. "HS-410 has been demonstrated to be well-tolerated by these patients, with no patients discontinuing treatment due to adverse events. This trend is in contrast to intravesical agents like BCG where the discontinuation rate is significant (approximately 25%)," said Gary D. Steinberg, M.D., Professor of Surgery and Director, Urologic Oncology, at The University of Chicago Medicine, and lead study investigator. "Additionally, HS-410 is easy to administer and the level of patient interest is high for this intradermal therapy. As we prepare for Phase 3, we look forward to the Phase 2 results to extend this dataset with the combination therapy, as well as HS-410's potential as a monotherapy without BCG." For its ongoing Phase 2 trial, Heat recently announced that it has completed enrollment of the full 75 patients in the three blinded, randomized, placebo-controlled arms evaluating HS-410 in combination with BCG. Heat remains focused on enrolling the additional 25 patients for the one unblinded, open-label monotherapy arm. Topline efficacy, immune response and safety data are expected in the fourth quarter of 2016. The Phase 1 data were summarized in a poster entitled "Phase 1 Study of Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Treated with Vesigenurtacel-L (HS-410) After Bacillus Calmette-Guérin (BCG)" presented at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting & Associated Programs. The poster is accessible on Heat's corporate website at http://www.heatbio.com/news/eventspresentations. About HS-410 (vesigenurtacel-L) HS-410 is an investigational product candidate for NMIBC based on Heat's proprietary ImPACT immunotherapy platform, designed to generate CD8+ "killer" T cells that attack cancer cells. HS-410 is currently being evaluated in an ongoing Phase 2, placebo controlled, 100-patient NMIBC trial at multiple centers and has been granted U.S. FDA Fast Track Designation for the treatment of NMIBC. Topline data from the Phase 2 trial are anticipated in the fourth quarter of 2016. About the Phase 1 NMIBC Trial According to the American Cancer Society, bladder cancer is the fifth most common cancer in the U.S., with approximately 75,000 new cases and 16,000 deaths in 2015. About 75% of the newly diagnosed patients have NMIBC. A key issue for bladder cancer is the high rate of recurrence, for which limited treatment options are available beyond complete bladder removal. The Phase 1 open-label, multicenter safety trial tested HS-410, after standard of care BCG, in 10 patients with NMIBC. Patients received the standard BCG treatment for 3-6 weeks, followed by weekly intradermal injections of HS-410 for 12 weeks and subsequent monthly HS-410 injections for 3 months. Subsequent maintenance BCG was administered at the discretion of the study investigator.
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent NHWK News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/22/2024 09:00:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:52:07 PM
- Scorpius Holdings Awarded Contract in Excess of $1 Million with NIH-Funded Researcher at a Major University • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Scorpius Holdings Accepted as a Member of the US Government’s BioMaP-Consortium • GlobeNewswire Inc. • 03/14/2024 12:30:00 PM
- Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend] • Edgar (US Regulatory) • 03/13/2024 10:17:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2024 10:01:13 AM
- Scorpius Holdings, Inc. Announces Closing of Public Offering • GlobeNewswire Inc. • 03/12/2024 09:00:59 PM
- Scorpius Holdings, Inc. Announces Pricing of Public Offering • GlobeNewswire Inc. • 03/08/2024 05:20:00 AM
- Scorpius Holdings, Inc. Announces Proposed Public Offering of Common Stock • GlobeNewswire Inc. • 03/07/2024 09:18:08 PM
- Scorpius Holdings Estimates Greater than 375% Sequential Increase in Revenue for the Fourth Quarter of 2023 Compared to the Third Quarter of 2023 • GlobeNewswire Inc. • 03/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 02:34:04 PM
- NightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open Today • GlobeNewswire Inc. • 02/06/2024 01:00:00 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer • GlobeNewswire Inc. • 02/01/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 01:00:09 PM
- NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note • GlobeNewswire Inc. • 01/30/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 09:30:14 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Awarded Multimillion- Dollar Contract with a Publicly Traded Biotech Company to Support its Phase 2 Clinical Program • GlobeNewswire Inc. • 01/25/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 01:30:09 PM
- NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client • GlobeNewswire Inc. • 01/16/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:59:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:07 PM
- NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO • GlobeNewswire Inc. • 01/08/2024 01:30:00 PM
- NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:57:14 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM